20 results on '"Giampaolo Montesi"'
Number of results to display per page
Search Results
2. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial
- Author
-
Andrea Muratore, Carlo Aschele, Claudio Belluco, Giulia Capelli, Paolo Delrio, Francesca Bergamo, Angelo Restivo, Maria Antonietta Gambacorta, Daniela Rega, Michele Bonomo, Gaya Spolverato, Francesco Marchegiani, Paola Del Bianco, Silvia De Franciscis, Mario Guerrieri, Alessandro Perin, Giampaolo Montesi, Claudio Coco, Valeria Palatucci, Emilio Morpurgo, Antonino Spinelli, Salvatore Ramuscello, and Salvatore Pucciarelli
- Subjects
medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Urology ,Surgical oncology ,medicine ,Humans ,In patient ,Prospective Studies ,Watchful Waiting ,Neoadjuvant therapy ,Chemotherapy ,integumentary system ,Rectal Neoplasms ,business.industry ,Incidence (epidemiology) ,Rectum ,Chemoradiotherapy ,medicine.disease ,Total mesorectal excision ,Neoadjuvant Therapy ,Treatment Outcome ,Oncology ,Surgery ,Neoplasm Recurrence, Local ,business - Abstract
BACKGROUND Rectum-preservation for locally advanced rectal cancer has been proposed as an alternative to total mesorectal excision (TME) in patients with major (mCR) or complete clinical response (cCR) after neoadjuvant therapy. The purpose of this study was to report on the short-term outcomes of ReSARCh (Rectal Sparing Approach after preoperative Radio- and/or Chemotherapy) trial, which is a prospective, multicenter, observational trial that investigated the role of transanal local excision (LE) and watch-and-wait (WW) as integrated approaches after neoadjuvant therapy for rectal cancer. METHODS Patients with mid-low rectal cancer who achieved mCR or cCR after neoadjuvant therapy and were fit for major surgery were enrolled. Clinical response was evaluated at 8 and 12 weeks after completion of chemoradiotherapy. Treatment approach, incidence, and reasons for subsequent TME were recorded. RESULTS From 2016 to 2019, 160 patients were enrolled; mCR or cCR at 12 weeks was achieved in 64 and 96 of patients, respectively. Overall, 98 patients were managed with LE and 62 with WW. In the LE group, Clavien-Dindo 3+ complications occurred in three patients. The rate of cCR increased from 8- to 12-week restaging. Thirty-three (94.3%) of 35 patients with cCR had ypT0-1 tumor. At a median 24 months follow-up, a tumor regrowth was found in 15 (24.2%) patients undergoing WW. CONCLUSIONS LE for patients achieving cCR or mCR is safe. A 12-week interval from chemoradiotherapy completion to LE is correlated with an increased cCR rate. The risk of ypT > is reduced when LE is performed after cCR.
- Published
- 2021
3. PH-0112 Multicenter large retrospectIve database on SBRT for colorectal lung metastases: the LaIT-SABR study
- Author
-
Riccardo Valdagni, L. Vavassori, Michele Rigo, Marianna Alessandra Gerardi, B. De Bari, N. Di Muzio, Barbara Alicja Jereczek-Fossa, Vieri Scotti, Frank Lohr, M. Perna, Filippo Alongi, Luigi Corti, I. Fazio, R.M. Niespolo, G. Mortellaro, F.M. Aquilanti, Andrei Fodor, Paolo Borghetti, M.F. Osti, Luca Nicosia, A. Ravasio, Davide Franceschini, L. Frassinelli, A. Di Marzo, G. Gadducci, A. Iurato, Fabiola Paiar, D. Aiello, Alessio Bruni, F. Casamassima, Sara Ramella, Silvia Chiesa, Rosario Mazzola, F. Perrone Congedi, Stefano Arcangeli, Stefano Maria Magrini, M. Franceschini, Lorenzo Livi, M. Sepulcri, Francesco Pasqualetti, Claudia Sangalli, Marta Scorsetti, Ernesto Maranzano, Giampaolo Montesi, and V. Valentini
- Subjects
medicine.medical_specialty ,Lung ,medicine.anatomical_structure ,Oncology ,business.industry ,Medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,Radiology ,business ,SABR volatility model ,Retrospective database - Published
- 2021
- Full Text
- View/download PDF
4. Is It Time to Introduce PET/CT in Rectal Cancer Guidelines?
- Author
-
Federica Matteucci, Domenico Rubello, Anna Margherita Maffione, Paola Caroli, Giampaolo Montesi, and Patrick M. Colletti
- Subjects
medicine.medical_specialty ,Colorectal cancer ,Disease ,Adenocarcinoma ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Carcinoembryonic antigen ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Biopsy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Contraindication ,PET-CT ,biology ,medicine.diagnostic_test ,business.industry ,Rectal Neoplasms ,General Medicine ,medicine.disease ,Review article ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,biology.protein ,Radiology ,Radiopharmaceuticals ,business - Abstract
At the moment, international guidelines for rectal cancer suggest to consider F-FDG PET/CT scan in a few conditions: (1) at disease presentation in case of suspected or proven metastatic synchronous adenocarcinoma with potentially curable M1 disease; (2) in the recurrence workup for serial carcinoembryonic antigen level elevation; (3) in the recurrence workup with metachronous metastases documented by CT, MRI, or biopsy; (4) in case of strong contraindication to IV contrast agent administration; and (5) to evaluate an equivocal finding on a contrast-enhanced CT or MRI. PET/CT is not indicated in the follow-up or surveillance of rectal cancer. On the other hand, an attentive evaluation of the literature shows that PET/CT may also be used in some circumstances with significant levels of diagnostic accuracy. This review article aims to emphasize differences between current international guidelines and scientific literature in the role of PET/CT in rectal cancer.
- Published
- 2020
5. Radiotherapy during COVID-19 pandemic. How to create a No fly zone: a Northern Italy experience
- Author
-
Giovanni Pavanato, Sara Chierchini, Giampaolo Montesi, Saide Di Biase, Mandoliti G, Edgardo Contato, and Graziella Elia Virdis
- Subjects
Short Communication ,medicine.medical_treatment ,Pneumonia, Viral ,Radiation oncology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Pandemic ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Pandemics ,Protocol (science) ,Clinical governance ,Cross Infection ,Infection Control ,Radiology Department, Hospital ,Radiotherapy ,medicine.diagnostic_test ,SARS-CoV-2 ,business.industry ,COVID-19 ,Interventional radiology ,General Medicine ,medicine.disease ,Triage ,Discontinuation ,EXPOSE ,Coronavirus ,Radiation therapy ,Italy ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Medical emergency ,Coronavirus Infections ,business - Abstract
Background SARS-CoV-2 pandemic represents a troubling health emergency but also a main challenge for the clinical governance of the system. Discontinuation of radiation treatments is not desirable and potentially life-threatening. On the other hand, accesses to hospital expose cancer patients to an increased risk of COVID-19 infection. We report our extended protocol, draft to manage clinical activities in our radiotherapy department, by minimizing contagion risks. Methods We used telephonic screening to assess the need for patient admission. A telephonic triage was performed to identify the presence of COVID-19 infection risk factors or symptoms. New treatments were stratified according to priority codes. A reserved entrance to radiotherapy department was assured for patients and staff. Surgical disposable mask was required for patients and caregivers. The activities were distributed during the whole workday, avoiding overlap to reduce aggregation. Results From 1st February 2020 to 31 March 2020, we reported an increase in the number of first medical examinations and treatments, compared to the same period of the previous year. Outpatients first medical examinations have been spread over the 12 working hours. No COVID-19 cases were detected. Conclusion During COVID-19 pandemic, we introduced procedures that allowed us to ensure the continuity in oncological cares, with limited risks of infection for patients and staff.
- Published
- 2020
- Full Text
- View/download PDF
6. Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis
- Author
-
Cynthia Aristei, Isabella Palumbo, Marco Lupattelli, Giampaolo Montesi, Vittorio Bini, Stefano Saccia, Nunzia Cenci, Alessandro Marchionni, Pietro Chiarini, and C. Zucchetti
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Survival ,Kaplan-Meier Estimate ,Radiosurgery ,Boost ,Fractionated stereotactic radiotherapy ,Glioblastoma ,Toxicity ,Stereotactic radiotherapy ,Cohort Studies ,Internal medicine ,medicine ,Overall survival ,Humans ,Survival analysis ,Aged ,Proportional Hazards Models ,business.industry ,Brain Neoplasms ,Radiotherapy Planning, Computer-Assisted ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Treatment Outcome ,Cohort ,Female ,Dose Fractionation, Radiation ,business ,Tomography, X-Ray Computed ,Radiotherapy, Image-Guided - Abstract
Aim To retrospectively assess toxicity and survival in 15 selected Glioblastoma patients treated with a sequential fractionated stereotactic radiotherapy (FSRT) boost after chemo-radiotherapy (CHT-RT) and compare their survival outcomes with a control group. Patients and methods Toxicity was assessed with the CTCAE 3.0 scale. The Kaplan-Meier method was used to design survival curves, log-rank test for bivariate analysis and Cox proportional hazard regression model for multivariate analysis. Results The median follow-up was 16 months (range=5-60). One case of headache and one of radionecrosis (RN) occurred. Median overall survival (OS) was 25 months in the boost group vs. 14 in the no-boost group (p=0.004). Median progression-free survival (PFS) was 15 months in the boost group versus 8 in the no-boost group (p=0.046). At multivariate analysis FSRT boost resulted significantly associated with OS and PFS. Conclusion In our series a sequential FSRT boost resulted in safe outcomes and significantly associated with survival.
- Published
- 2020
7. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study
- Author
-
Angelo, Porreca, Marianna, Noale, Walter, Artibani, Pier Francesco Bassi, Filippo, Bertoni, Sergio, Bracarda, Giario Natale Conti, Renzo, Corvò, Mauro, Gacci, Pierpaolo, Graziotti, Magrini, STEFANO MARIA, Vincenzo, Mirone, Rodolfo, Montironi, Giovanni, Muto, Stefano, Pecoraro, Umberto, Ricardi, Elvio, Russi, Andrea, Tubaro, Vittorina, Zagonel, Gaetano, Crepaldi, Stefania, Maggi, Pierfrancesco, Bassi, Stefano Maria Magrini, Anna Rita Alitto, Enrica, Ambrosi, Alessandro, Antonelli, Cynthia, Aristei, Michele, Barbieri, Franco, Bardari, Lilia, Bardoscia, Salvina, Barra, Sara, Bartoncini, Umberto, Basso, Carlotta, Becherini, Rita, Bellavita, Franco, Bergamaschi, Stefania, Berlingheri, Berruti, Alfredo, Marco, Borghesi, Roberto, Bortolus, Valentina, Borzillo, Davide, Bosetti, Giuseppe, Bove, Pierluigi, Bove, Maurizio, Brausi, Alessio, Bruni, Giorgio, Bruno, Eugenio, Brunocilla, Alberto, Buffoli, BUGLIONE DI MONALE E BASTIA, Michela, Consuelo, Buttigliero, Giovanni, Cacciamani, Michela, Caldiroli, Giuseppe, Cardo, Giorgio, Carmignani, Giuseppe, Carrieri, Emanuele, Castelli, Elisabetta, Castrezzati, Gianpiero, Catalano, Susanna, Cattarino, Francesco, Catucci, Francolini Dario Cavallini, Ofelia, Ceccarini, Antonio, Celia, Francesco, Chiancone, Tommaso, Chini, Claudia, Cianci, Antonio, Cisternino, Devis, Collura, Franco, Corbella, Matteo, Corinti, Paolo, Corsi, Fiorenza, Cortese, Luigi, Corti, Cosimo de Nunzio, Olga, Cristiano, Rolando, M D'Angelillo, Luigi Da Pozzo, Daniele, D'Agostino, Carolina, D'Elia, Matteo, Dandrea, Michele De Angelis, Paolo De Angelis, Ottavio De Cobelli, Bernardino De Concilio, Antonello De Lisa, Stefano De Luca, Agostina De Stefani, Chiara Lucrezia Deantoni, Esposti Claudio Degli, Anna, Destito, Beatrice, Detti, Nadia Di Muzio, Andrea Di Stasio, Calogero Di Stefano, Danilo Di Trapani, Giuseppe, Difino, Sara, Falivene, Giuseppe, Farullo, Paolo, Fedelini, Ilaria, Ferrari, Francesco, Ferrau, Matteo, Ferro, Andrei, Fodor, Francesco, Fontanta, Francesco, Francesca, Giulio, Francolini, Paolo, Frata, Giovanni, Frezza, Pietro, Gabriele, Maria, Galeandro, Elisabetta, Garibaldi, Pietro Giovanni Gennari, Alessandro, Gentilucci, Alessandro, Giacobbe, Laura, Giussani, Giuseppe, Giusti, Paolo, Gontero, Alessia, Guarneri, Cesare, Guida, Alberto, Gurioli, Dorijan, Huqi, Ciro, Imbimbo, Gianluca, Ingrosso, Cinzia, Iotti, Corrado, Italia, Pierdaniele La Mattina, Enza, Lamanna, Luciana, Lastrucci, Grazia, Lazzari, Fabiola, Liberale, Giovanni, Liguori, Roberto, Lisi, Frank, Lohr, Riccardo, Lombardo, Jon A, J Lovisolo, Giuseppe Mario Ludovico, Nicola, Macchione, Francesca, Maggio, Michele, Malizia, Gianluca, Manasse, Giovanni, Mandoliti, Giovanna, Mantini, Luigi, Marafioti, Luisa, Marciello, Alberto Mario Marconi, Antonietta, Martilotta, Salvino, Marzano, Stefano, Masciullo, Gloria, Maso, Adele, Massenzo, Ercole, Mazzeo, Luigi, Mearini, Serena, Medoro, Rosa, Molè, Giorgio, Monesi, Emanuele, Montanari, Franco, Montefiore, Giampaolo, Montesi, Giuseppe, Morgia, Gregorio, Moro, Giorgio, Muscas, Daniela, Musio, Paolo, Muto, Giovanni, Muzzonigro, Giorgio, Napodano, Carlo Luigi Augusto Negro, Mattia, Nidini, Maria, Ntreta, Marco, Orsatti, Carmela, Palazzolo, Isabella, Palumbo, Alessandro, Parisi, Paolo, Parma, Nicola, Pavan, Martina, Pericolini, Francesco, Pinto, Antonio, Pistone, Valerio, Pizzuti, Angelo, Platania, Caterina, Polli, Giorgio, Pomara, Elisabetta, Ponti, Antonio Benito Porcaro, Francesco, Porpiglia, Dario, Pugliese, Armin, Pycha, Giuseppe, Raguso, Andrea, Rampini, Donato Franco Randone, Valentina, Roboldi, Marco, Roscigno, Maria Paola Ruggieri, Giuseppe, Ruoppo, Roberto, Sanseverino, Anna, Santacaterina, Michele, Santarsieri, Riccardo, Santoni, Sarah, Scagliarini, Giorgio Vittorio Scagliotti, Mauro, Scanzi, Marcello, Scarcia, Riccardo, Schiavina, Alessandro, Sciarra, Carmine, Sciorio, Tindaro, Scolaro, Salvatore, Scuzzarella, Oscar, Selvaggio, Armando, Serao, Sergio, Serni, Marco Andrea Signor, Mauro, Silvani, Giovanni, Silvano, Franco, Silvestris, Simeone, Claudio, Valeria, Simone, Girolamo, Spagnoletti, Matteo Giulio Spinelli, Luigi, Squillace, Vincenzo, Tombolini, Mariastella, Toninelli, Triggiani, Luca, Alberto, Trinchieri, Luca Eolo Trodella, Lucio, Trodella, Carlo, Trombetta, Lidia, Tronnolone, Marcello, Tucci, Daniele, Urzì, Riccardo, Valdagni, Maurizio, Valeriani, Maurizio, Vanoli, Elisabetta, Vitali, Alessandro, Volpe, Stefano, Zaramella, Guglielmo, Zeccolini, Giampaolo, Zini, Porreca, Angelo, Noale, Marianna, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Ricardi, Umberto, Russi, Elvio, Tubaro, Andrea, Zagonel, Vittorina, Crepaldi, Gaetano, Maggi, Stefania, Gaetano, Crepaldi, Umberto, Basso, Luigi, Corti, D'Agostino, Daniele, Matteo, Dandrea, Davide, Bosetti, Gianpiero, Catalano, Ottavio, De Cobelli, Lucrezia, Deantoni Chiara, Nadia, Di Muzio, Ferro, Matteo, Andrei, Fodor, Pierdaniele, La Mattina, Emanuele, Montanari, Barbieri, Michele, Valentina, Borzillo, Chiancone, Francesco, Sara, Falivene, Paolo, Fedelini, Imbimbo, Ciro, Paolo, Muto, Sarah, Scagliarini, Giovanni, Muzzonigro, Enrica, Ambrosi, Alessandro, Antonelli, Lilia, Bardoscia, Stefania, Berlingheri, Alfredo, Berruti, Alberto, Buffoli, Michela, Buglione, Mauro, Scanzi, Elisabetta, Castrezzati, Paolo, Frata, Giulio, Francolini, Beatrice, Detti, Tommaso, Chini, Carlotta, Becherini, Olga, Cristiano, Cesare, Guida, Sara, Bartoncini, Consuelo, Buttigliero, Emanuele, Castelli, Devis, Collura, Stefano, De Luca, Pietro, Gabriele, Elisabetta, Garibaldi, Alessandro, Giacobbe, Paolo, Gontero, Alessia, Guarneri, Alberto, Gurioli, Francesco, Porpiglia, Franco, Randone Donato, Vittorio, Scagliotti Giorgio, Cynthia, Aristei, Rita, Bellavita, Isabella, Palumbo, Franco, Bardari, Augusto, Negro Carlo Luigi, Franco, Bergamaschi, Maria, Galeandro, Cinzia, Iotti, Giuseppe, Raguso, Paola, Ruggieri Maria, Giuseppe, Ruoppo, Marco, Borghesi, Eugenio, Brunocilla, Claudio, Degli Esposti, Giovanni, Frezza, Michele, Malizia, Maria, Ntreta, Alessandro, Parisi, Riccardo, Schiavina, Roberto, Bortolu, Giuseppe, Bove, Antonio, Cisternino, Carrieri, Giuseppe, Giuseppe, Difino, Oscar, Selvaggio, Maurizio, Brausi, Alessio, Bruni, Frank, Lohr, Ercole, Mazzeo, Enza, Lamanna, Calogero, Di Stefano, Giorgio, Bruno, Michela, Caldiroli, Ilaria, Ferrari, Laura, Giussani, Lovisolo Jon, A. J., Mario, Marconi Alberto, Giuseppe, Cardo, Mario, Ludovico Giuseppe, Marcello, Scarcia, Giorgio, Carmignani, Salvina, Barra, Dario, Cavallini Francolini, Franco, Corbella, Ofelia, Ceccarini, Luigi, Da Pozzo, Agostina, De Stefani, Corrado, Italia, Stefano, Masciullo, Valentina, Roboldi, Marco, Roscigno, Antonio, Celia, Bernardino, De Concilio, Claudia, Cianci, Francesco, Francesca, Giorgio, Pomara, Michele, Santarsieri, Fiorenza, Cortese, Andrea, Di Stasio, Franco, Montefiore, Armando, Serao, D'Elia, Carolina, Armin, Pycha, Dorijan, Huqi, Paolo, De Angeli, Nicola, Macchione, Francesco, Fontanta, Giorgio, Monesi, Antonello, De Lisa, Giuseppe, Giusti, Giorgio, Musca, Anna, Destito, Rosa, Molè, Danilo, Di Trapani, Francesco, Ferrau, Carmela, Palazzolo, Angelo, Platania, Anna, Santacaterina, Grazia, Lazzari, Fabiola, Liberale, Gregorio, Moro, Giovanni, Liguori, Nicola, Pavan, Francesca, Maggio, Marco, Orsatti, Giovanni, Mandoliti, Giampaolo, Montesi, Luigi, Marafioti, Antonietta, Martilotta, Adele, Massenzo, Luisa, Marciello, Salvino, Marzano, Caterina, Polli, Gloria, Maso, Serena, Medoro, Giuseppe, Morgia, Napodano, Giorgio, Pistone, Antonio, Roberto, Sanseverino, Mattia, Nidini, Paolo, Parma, Valerio, Pizzuti, Sciorio, Carmine, Scuzzarella, Salvatore, Tindaro, Scolaro, Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S, Crepaldi G, Maggi S, Noale M, Porreca A, Artibani W, Bassi P, Bracarda S, Conti GN, Corvò R, Graziotti P, Russi E, Mirone V, Montironi R, Bertoni F, Gacci M, Magrini SM, Muto G, Pecoraro S, Ricardi U, Tubaro A, Zagonel V, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini FD, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Nunzio C, Cristiano O, D'Angelillo RM, Da Pozzo L, D'agostino D, D'Elia C, Dandrea M, De Angelis M, De Angelis P, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli EC, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, Ferro M, Fodor A, Fontanta F, Francesca F, Francolini G, Frata P, Frezza G, Gabriele P, Galeandro M, Garibaldi E, Gennari PG, Gentilucci A, Giacobbe A, Giussani L, Giusti G, Gontero P, Guarneri A, Guida C, Gurioli A, Huqi D, Imbimbo C, Ingrosso G, Iotti C, Italia C, La Mattina P, Lamanna E, Lastrucci L, Lazzari G, Liberale F, Liguori G, Lisi R, Lohr F, Lombardo R, Lovisolo JAJ, Ludovico GM, Macchione N, Maggio F, Malizia M, Manasse G, Mandoliti G, Mantini G, Marafioti L, Marciello L, Marconi AM, Martilotta A, Marzano S, Masciullo S, Maso G, Massenzo A, Mazzeo E, Mearini L, Medoro S, Molè R, Monesi G, Montanari E, Montefiore F, Montesi G, Morgia G, Moro G, Muscas G, Musio D, Muto P, Muzzonigro G, Napodano G, Negro CLA, Nidini M, Ntreta M, Orsatti M, Palazzolo C, Palumbo I, Parisi A, Parma P, Pavan N, Pericolini M, Pinto F, Pistone A, Pizzuti V, Platania A, Polli C, Pomara G, Ponti E, Porcaro AB, Porpiglia F, Pugliese D, Pycha A, Raguso G, Rampini A, Randone DF, Roboldi V, Roscigno M, Ruggieri MP, Ruoppo G, Sanseverino R, Santacaterina A, Santarsieri M, Santoni R, Scagliarini S, Scagliotti GV, Scanzi M, Scarcia M, Schiavina R, Sciarra A, Sciorio C, Scolaro T, Scuzzarella S, Selvaggio O, Serao A, Serni S, Signor MA, Silvani M, Silvano G, Silvestris F, Simeone C, Simone V, Spagnoletti G, Spinelli MG, Squillace L, Tombolini V, Toninelli M, Triggiani L, Trinchieri A, Trodella LE, Trodella L, Trombetta C, Tronnolone L, Tucci M, Urzì D, Valdagni R, Valeriani M, Vanoli M, Vitali E, Volpe A, Zaramella S, Zeccolini G, Zini G, Porreca, A., Noale, M., Artibani, W., Bassi, P. F., Bertoni, F., Bracarda, S., Conti, G. N., Corvo, R., Gacci, M., Graziotti, P., Magrini, S. M., Mirone, V., Montironi, R., Muto, G., Pecoraro, S., Ricardi, U., Russi, E., Tubaro, A., Zagonel, V., Crepaldi, G., Maggi, S., Alitto, A. R., Ambrosi, E., Antonelli, A., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Maurizio, B., Alessio, B., Giorgio, B., Eugenio, B., Alberto, B., Michela, B., Consuelo, B., Giovanni, C., Michela, C., Giuseppe, C., Giorgio, C., Emanuele, C., Elisabetta, C., Gianpiero, C., Susanna, C., Catucci, F., Dario, C. F., Ofelia, C., Antonio, C., Francesco, C., Tommaso, C., Claudia, C., Devis, C., Franco, C., Matteo, C., Paolo, C., Fiorenza, C., Luigi, C., Cosimo, N., Cristiano, O., D'Angelillo, R. M., Da Pozzo, L., D'Agostino, D., D'Elia, C., Dandrea, M., De Angelis, M., De Angelis, P., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli, E. C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontanta, F., Francesca, F., Francolini, G., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari, P. G., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J. A. J., Ludovico, G. M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi, A. M., Martilotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone, D. F., Roboldi, V., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti, G. V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simeone, C., Simone, V., Spagnoletti, G., Spinelli, M. G., Squillace, L., Tombolini, V., Toninelli, M., Triggiani, L., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Volpe, A., Zaramella, S., Zeccolini, G., Zini, G., Porreca, A, Noale, M, Artibani, W, Bassi, P, Bertoni, F, Bracarda, S, Conti, G, Corvò, R, Gacci, M, Graziotti, P, Magrini, S, Mirone, V, Montironi, R, Muto, G, Pecoraro, S, Ricardi, U, Russi, E, Tubaro, A, Zagonel, V, Crepaldi, G, Maggi, S, and Da Pozzo, L
- Subjects
Male ,030232 urology & nephrology ,Severity of Illness Index ,Prostate cancer ,0302 clinical medicine ,Quality of life ,Activities of Daily Living ,Diagnosis ,Medicine ,Age Factor ,Prospective Studies ,Prospective cohort study ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Age Factors ,Pros-IT CNR study ,General Medicine ,Health Survey ,Middle Aged ,Neoadjuvant Therapy ,3. Good health ,Italy ,030220 oncology & carcinogenesis ,lcsh:R858-859.7 ,Regression Analysis ,Public Health ,Human ,Diagnosi ,prostate cancer, survival, quality of life ,medicine.medical_specialty ,lcsh:Computer applications to medicine. Medical informatics ,Regression Analysi ,03 medical and health sciences ,Percutaneous Coronary Intervention ,Internal medicine ,Severity of illness ,Humans ,Aged ,Cancer staging ,business.industry ,Research ,Environmental and Occupational Health ,Public Health, Environmental and Occupational Health ,Prostatic Neoplasms ,Cancer ,medicine.disease ,Health Surveys ,Comorbidity ,Quality of Life ,Prospective Studie ,Settore MED/24 ,Prostatic Neoplasm ,business ,Sexual function - Abstract
Background The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer is diagnosed. Methods One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12). Results At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one. Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower sexual function scores at diagnosis. Conclusions Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different profile of care.
- Published
- 2018
8. PO-0846: Preliminary outcome results of a PET-CT based direct planning protocol in head and neck radiotherapy
- Author
-
S. Di Biase, L. Rampin, A. Ferretti, E. Bellan, G. Virdis, Giampaolo Montesi, M. Maffione, Giovanni Pavanato, F. Perrotti, and Giovanni Mandoliti
- Subjects
Protocol (science) ,medicine.medical_specialty ,PET-CT ,Oncology ,Head and neck radiotherapy ,business.industry ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,Radiology ,business ,Outcome (game theory) - Published
- 2020
- Full Text
- View/download PDF
9. PREST: Pain REduction with bone metastases STereotactic radiotherapy: A phase III randomized multicentric trial
- Author
-
M. Santarelli, Giampaolo Montesi, Masiello, Francesco Cellini, Alessio G. Morganti, Salvatore Parisi, Savino Cilla, Stefano Pergolizzi, Antonino D'Agostino, Giambattista Siepe, C.M. Donati, Francesco Pastore, Francesco Deodato, Ernesto Maranzano, Rossella Di Franco, Paolo Muto, Salatino A, Stefania Manfrida, Valentini, Anna Santacaterina, Fabio Arcidiacono, and Fusco
- Subjects
Stereotactic radiotherapy ,medicine.medical_specialty ,Text mining ,Pain reduction ,business.industry ,medicine ,Radiology ,business - Abstract
Background Palliative antalgic treatments represent an issue for clinical management and a challenge for scientific research. Radiotherapy (RT) plays a central role. Techniques such as stereotactic body radiotherapy (SBRT) were largely investigated in several phase 2 studies with good symptom response, becoming widely adopted. Still is lacking evidence from randomized, direct comparison of RT and SBRT. Methods/Design The PREST trial was designed as an interventional study without medicinal, randomized 1:1, open-label, multicentric, phase 3. Inclusion criteria: painful spinal bone metastases presenting pain level >4 (or >1 if assuming analgesic) at numeric rating scale (NRS); expected intermediate/high prognosis (superior to 6 months) according to the Mizumoto prognostic score; low spine instability neoplastic score (SINS) sores (
- Published
- 2019
- Full Text
- View/download PDF
10. Pain REduction with bone metastases STereotactic radiotherapy (PREST): A phase III randomized multicentric trial
- Author
-
Maria Antonietta Gambacorta, Vincenzo Valentini, Francesco Cellini, Alessio G. Morganti, Giambattista Siepe, C.M. Donati, Antonia Salatino, Vincenzo Fusco, V. Borzillo, Anna Santacaterina, Rossella Di Franco, Matteo Muto, Antonino D'Agostino, Francesco Pastore, Paolo Muto, Salvatore Parisi, Savino Cilla, Stefano Pergolizzi, Renzo Corvò, Stefania Manfrida, Giampaolo Montesi, Fabio Arcidiacono, Valeria Masiello, Francesco Deodato, Ernesto Maranzano, Mario Santarelli, Cellini F., Manfrida S., Deodato F., Cilla S., Maranzano E., Pergolizzi S., Arcidiacono F., Di Franco R., Pastore F., Muto M., Borzillo V., Donati C.M., Siepe G., Parisi S., Salatino A., D'Agostino A., Montesi G., Santacaterina A., Fusco V., Santarelli M., Gambacorta M.A., Corvo R., Morganti A.G., Masiello V., Muto P., and Valentini V.
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Analgesic ,Medicine (miscellaneous) ,Radiosurgery ,030218 nuclear medicine & medical imaging ,law.invention ,Lesion ,03 medical and health sciences ,Study Protocol ,0302 clinical medicine ,Quality of life ,Randomized controlled trial ,law ,Outcome Assessment, Health Care ,medicine ,Clinical endpoint ,Humans ,Simultaneous integrated boost ,Pharmacology (medical) ,Progression-free survival ,Pain control ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Randomised controlled trial ,lcsh:R5-920 ,Spinal Neoplasms ,medicine.diagnostic_test ,business.industry ,Bone metastases ,Magnetic resonance imaging ,Cancer Pain ,Magnetic Resonance Imaging ,Radiation therapy ,Bone metastase ,030220 oncology & carcinogenesis ,Radiology ,Radiotherapy, Intensity-Modulated ,medicine.symptom ,lcsh:Medicine (General) ,business - Abstract
Background Palliative antalgic treatments represent an issue for clinical management and a challenge for scientific research. Radiotherapy (RT) plays a central role. Techniques such as stereotactic body radiotherapy (SBRT) were largely investigated in several phase 2 studies with good symptom response, becoming widely adopted. However, evidence from randomized, direct comparison of RT and SBRT is still lacking. Methods/design The PREST trial was designed as an interventional study without medicinal treatment. It is a phase 3, open-label, multicentric trial randomized 1:1. Inclusion criteria include painful spinal bone metastases presenting with a pain level > 4 (or > 1 if being treated with an analgesic) on the Numeric Rating Scale (NRS); expected intermediate/high prognosis (greater than 6 months) according to the Mizumoto prognostic score; low spine instability neoplastic score (SINS) sores ( Discussion The primary endpoint is overall pain reduction, defined in terms of variation between baseline and 3-month evaluation; pain will be measured using the NRS. Secondary endpoints include pain control duration; retreatment rates (after a minimum interval of 1 month); local control assessed with RECIST criteria; symptom progression free survival; progression-free survival; overall survival; and quality of life (at 0, 30, and 90 days). Accrual of 330 lesions is planned. The experimental arm is expected to have an improvement in overall pain response rates of 15% with respect to the standard arm (60% according to Chow et al. (Int J Radiat Oncol Biol Phys. 82(5):1730–7, 2012)). Trial registration ClinicalTrials.gov, NCT03597984. Registered on July 2018.
- Published
- 2019
11. Radiotherapy for Early-Stage Prostate Cancer in Men under 70 Years of Age
- Author
-
Giampaolo Montesi, Melissa Scricciolo, Cynthia Aristei, Isabella Palumbo, Marco Lupattelli, Valentina Lancellotta, Fabio Arcidiacono, Rita Bellavita, Vittorio Bini, and C. Zucchetti
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_treatment ,030232 urology & nephrology ,Kaplan-Meier Estimate ,Gastroenterology ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,Medicine ,Neoadjuvant therapy ,Radical radiotherapy ,Age Factors ,Radiotherapy Dosage ,General Medicine ,Middle Aged ,Prognosis ,Neoadjuvant Therapy ,Prostate-specific antigen ,Treatment Outcome ,Dose ,030220 oncology & carcinogenesis ,Toxicity ,Adenocarcinoma ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,Urogenital System ,Disease-Free Survival ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,Biomarkers, Tumor ,Humans ,Aged ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Prostatic Neoplasms ,Retrospective cohort study ,Prostate-Specific Antigen ,medicine.disease ,Acute toxicity ,Gastrointestinal Tract ,Radiation therapy ,Neoplasm Grading ,Radiotherapy, Conformal ,business ,Follow-Up Studies - Abstract
Aims To demonstrate that radiotherapy (RT) is a valid alternative to surgery in men ≤70 years old with localized prostate cancer. Methods From 1988 to 2009, 214 patients with T1-2 N0 M0 prostate cancer were treated with RT. The effects of patient- and treatment-related risk factors on toxicity were investigated. Results Median follow-up was 105 months (range 14.2-180). The 5-, 10-, and 15-year biochemical relapse-free survival for all 214 patients was 80%, 61.9%, and 57.5%, respectively. In bivariate analysis, age (≤65 vs 65-70 years) was not a significant factor for biochemical relapse, while radiation dose was (p = 0.05) in multivariate analysis. Cancer-specific survival rates at 5, 10, and 15 years were 98.4%, 93.2%, and 69.7%, respectively. Median overall survival (OS) was 167 months (95% confidence interval 147.3-186.7). The OS rates at 5, 10, and 15 years were 91.8%, 75.8%, and 42.5%, respectively. Acute genitourinary (GU) and gastrointestinal (GI) toxicities occurred in 105 (49%) and 98 patients (45.8%), respectively, with only 2 cases of grade III GI toxicity. Late GU and GI toxicities occurred in 17 (7.9%) and 20 (9.3%) patients, respectively, with 1 grade III GI toxicity and 2 grade III GU toxicities. Risk factors for late toxicity were age and RT dose and technique, which were unrelated to acute toxicity. Conclusions Age ≤70 years does not consistently confer a negative prognosis for localized prostate cancer. Radiotherapy appears to be a viable alternative to surgery, offering excellent long-term cancer control.
- Published
- 2015
- Full Text
- View/download PDF
12. Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study
- Author
-
Alessandro Frattegiani, C. Mariucci, Isabella Palumbo, E. Arena, Lorenzo Falcinelli, Giampaolo Montesi, Rita Bellavita, Fabio Matrone, Cynthia Aristei, Marco Lupattelli, Vittorio Bini, and Simonetta Saldi
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Intensity-modulated radiotherapy ,Urology ,Rectum ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,Prostate ,Internal medicine ,Acute rectal toxicity ,medicine ,Humans ,Prospective Studies ,Radiation Injuries ,Radiometry ,Prospective cohort study ,Aged ,Aged, 80 and over ,Univariate analysis ,business.industry ,Statins ,Prostatic Neoplasms ,Common Terminology Criteria for Adverse Events ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prostate-specific antigen ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Hormonal therapy ,Hypofractionation ,Dose Fractionation, Radiation ,Radiotherapy, Intensity-Modulated ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business - Abstract
AIM To analyze risk factors for acute rectal toxicity during hypofractionated intensity-modulated radiotherapy (IMRT) for prostate cancer. PATIENTS AND METHODS A total of 195 patients received 74.25 Gy in 33 fractions to the prostate and, if involved, to the seminal vescicles (SV). When the risk of SV involvement was >15% according to the Roach's formula, they received 62 Gy in 33 fractions. Overall, 107/195 patients (54.87%) received hormonal therapy (luteinizing hormone-releasing hormone analogue, anti-androgen, or both). Common Terminology Criteria for Adverse Events version 3.0 was used to classify rectal toxicity. RESULTS Acute rectal toxicity occurred in 79 (40.51%) patients (grade 1 in 44). In univariate analysis, use of calcium channel blockers significantly reduced the acute rectal toxicity rate and 3-hydroxy-methylglutaryl CoA reductase inhibitors (statins) significantly reduced the rectal toxicity rate and grade. In multivariate analysis, only statin use was an independent protective factor. CONCLUSION In patients with prostate cancer treated with a moderate hypofractionated IMRT schedule, use of statins lowered the incidence and grade of acute rectal toxicity.
- Published
- 2017
13. EP-1527: Pelvic Intensity-Modulated Radiotherapy in prone and supine position in gynaecological cancer
- Author
-
M. Marcantonini, A. Didona, Valentina Lancellotta, Giampaolo Montesi, A. Cavalli, S. Saccia, Elisabetta Perrucci, Cynthia Aristei, C. Mariucci, Vittorio Bini, and M. Mendichi
- Subjects
medicine.medical_specialty ,Supine position ,business.industry ,Hematology ,Gynaecological cancer ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,Intensity modulated radiotherapy ,business - Published
- 2017
- Full Text
- View/download PDF
14. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience
- Author
-
Isabella Palumbo, Elisabetta Perrucci, Valentina Lancellotta, C. Zucchetti, C. Mariucci, Stefano Saccia, Giampaolo Montesi, Vittorio Bini, and Cynthia Aristei
- Subjects
Adult ,medicine.medical_specialty ,Brachytherapy ,Endometrial cancer ,Relapse ,Vaginal Neoplasms ,medicine.medical_treatment ,Urology ,Disease-Free Survival ,030218 nuclear medicine & medical imaging ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Chronic toxicity ,Aged ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Surgery ,Endometrial Neoplasms ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Toxicity ,Vagina ,Lymphadenectomy ,Female ,Radiotherapy, Adjuvant ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Purpose To evaluate the incidences of vaginal recurrence and toxicity after vaginal brachytherapy in Stage I–II endometrial cancer. Methods and Materials Between 2003 and 2012, 150 high-intermediate-risk Stage I and 7 Stage II patients, median age 64 years, underwent surgery, with or without lymphadenectomy, and 3D brachytherapy: 7 Gy, at 5 mm depth from applicator surface, for 3-week fractions. The effects of age, grading, number of excised lymph nodes and pathologic stage on loco-regional relapse (LRR), metastases, and tumor-related death were investigated. Vaginal toxicity was evaluated during followup visits. Results At 83 months of median followup, 144 patients were disease free, 2 in relapse, 7 deceased from disease, and 4 from other causes. One vaginal (0.6%), five nodal (3.2%), three pelvic over the vaginal cuff (1.9%), and one distant recurrences were seen (0.6%). The 5-year probability of LRR-free, distant metastasis-free and cause-specific survivals for all patients were 93.6% (95% confidence interval [CI]: 88.1–96.7), 97.8% (95% CI: 93.2–99.3), and 96.5% (95% CI: 93.5–99.5) and for Stage I 95.7% (95% CI: 92.2–9.1), 99.3% (95% CI: 98.0–100), and 97.7% (95% CI: 95.2–100), respectively. At multivariate analysis, Stage II disease and more than 12 lymph nodes sampled were associated with LRR (hazard ratio [HR]: 3.88; 95% CI: 1.390–10.878; p = 0.010 and HR: 6.952; 95% CI: 1.591–30.385; p = 0.010) and Stage II with metastasis and tumor-related death (HR: 23.057; 95% CI: 2.296–231.485; p = 0.008 and HR: 4.324; 95% CI: 1.223–15.290; p = 0.023). Vaginal acute and chronic toxicity was 16% and 55.4%, respectively, all only Grades 1–2. Conclusions For high-to-intermediate-risk Stage I endometrial cancer, 3D vaginal brachytherapy achieved good local control and low toxicity. In Stage II, patients brachytherapy could be administered after complete surgical staging.
- Published
- 2015
15. Metachronous cardiac and cerebral sarcomas: case report with focus on molecular findings and review of the literature
- Author
-
Angelo Sidoni, Angela Guerriero, Giampaolo Montesi, Roberta La Starza, Stefano Pasquino, Paolo Giovenali, Cristina Mecucci, Tiziana Pierini, and Temistocle Ragni
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Monosomy ,Gliosarcoma ,12E7 Antigen ,medicine.disease_cause ,Asbestos ,Pathology and Forensic Medicine ,Synovial sarcoma ,Heart Neoplasms ,Fatal Outcome ,Multiple primary tumors ,Antigens, CD ,Neoplasms ,Asbestos exposure ,Cardiac sarcoma ,Brain Neoplasms ,Cell Adhesion Molecules ,Combined Modality Therapy ,Humans ,Immunohistochemistry ,Middle Aged ,Neoplasm Grading ,Neoplasms, Second Primary ,Sarcoma ,Vimentin ,medicine ,Mesothelioma ,Family history ,Antigens ,business.industry ,Cancer ,medicine.disease ,CD ,Second Primary ,business - Abstract
Although multiple primary malignancies are relatively rare, they have increased in frequency over the last decades, partly because of advances in diagnosis and therapy. This report describes for the first time the case of a patient with past occupational exposure to asbestos and no family history of cancer who developed 2 rare primary malignancies: a cardiac sarcoma and a gliosarcoma 11 months later. Molecular-cytogenetic studies did not identify common lesions to these 2 rare metachronous sarcomas. The gliosarcoma was associated with monosomy 10 and underlying PTEN monoallelic loss, which has been recurrently observed. In the cardiac sarcoma, MDM2 amplification and CDKN2AB/9p21 biallelic deletion suggested intimal sarcoma. No causal relationship was found between cardiac sarcoma and asbestos exposure, although MDM2 abnormalities were linked to malignant mesothelioma.
- Published
- 2015
16. PV-0326: Time to surgery and pCR after neoadjuvant CRT in rectal cancer: a population study on 2113 patients
- Author
-
L. Giaccherini, Gabriella Macchia, M.A. Gambacorta, Alessandra Galardi, A. De Paoli, Luciana Caravatta, Caterina Boso, Giampaolo Montesi, Mattia Falchetto Osti, Carlotta Masciocchi, Marco Lupattelli, Liliana Belgioia, M.E. Rosetto, F. Perrotti, Salvatore Parisi, Lucia Turri, R.M. Niespolo, Francesco Romeo Filippone, Giovanna Mantello, Piera Sciacero, V. Valentini, Giuditta Chiloiro, Alessio G. Morganti, Aldo Sainato, and A. Fontana
- Subjects
medicine.medical_specialty ,Oncology ,Colorectal cancer ,business.industry ,Time to surgery ,medicine ,Population study ,Radiology, Nuclear Medicine and imaging ,Hematology ,medicine.disease ,business ,Surgery - Published
- 2017
- Full Text
- View/download PDF
17. Short-course radiotherapy with delayed surgery in unfit locally advanced rectal cancer patients
- Author
-
Cynthia Aristei, Marco Lupattelli, Danilo Castellani, Valentina Lancellotta, Isabella Palumbo, Vittorio Bini, Lorenzo Falcinelli, and Giampaolo Montesi
- Subjects
rectal cancer, radiotherapy ,medicine.medical_specialty ,Rectal Neoplasms ,business.industry ,Colorectal cancer ,General surgery ,Gastroenterology ,Locally advanced ,030230 surgery ,Hepatology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Delayed surgery ,Humans ,Neoplasm Recurrence, Local ,rectal cancer ,business ,radiotherapy ,Aged ,Neoplasm Staging ,Short course radiotherapy - Published
- 2015
- Full Text
- View/download PDF
18. EP-1260: Risk factors for acute toxicity in prostate cancer patients receiving hypofractionated IMRT
- Author
-
Giampaolo Montesi, S. Cusco, Rita Bellavita, Simonetta Saldi, C. Zucchetti, Cynthia Aristei, Alessandro Frattegiani, Marco Lupattelli, Vittorio Bini, and Fabio Matrone
- Subjects
Oncology ,medicine.medical_specialty ,Prostate cancer ,business.industry ,Radiology Nuclear Medicine and imaging ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,medicine.disease ,business ,Acute toxicity - Published
- 2015
- Full Text
- View/download PDF
19. Does ultrasound provide any added value in breast contouring for radiotherapy after conserving surgery for cancer?
- Author
-
C. Zucchetti, G. Gobbi, Barbara Palumbo, Cynthia Aristei, Valentina Lancellotta, Giampaolo Montesi, Isabella Palumbo, Vittorio Bini, Rossana Crisci, Laura Cardinali, and Lorenzo Falcinelli
- Subjects
Adult ,medicine.medical_specialty ,Breast contouring ,medicine.medical_treatment ,Breast Neoplasms ,Mastectomy, Segmental ,Palpation ,Breast conserving surgery ,Intra-modality variability ,Palpation vs ultrasound vs CT ,Radiotherapy ,Breast cancer ,Whole Breast Irradiation ,medicine ,Breast-conserving surgery ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,skin and connective tissue diseases ,Aged ,Ultrasonography ,Contouring ,medicine.diagnostic_test ,business.industry ,Research ,Radiotherapy Planning, Computer-Assisted ,Ultrasound ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,Oncology ,Radiology Nuclear Medicine and imaging ,Female ,Tomography ,Radiology ,Tomography, X-Ray Computed ,business - Abstract
Background Whole breast irradiation after conserving surgery for breast cancer requires precise definition of the target volume. The standard approach uses computed tomography (CT) images. However, since fatty breast and non-breast tissues have similar electronic densities, difficulties in differentiating between them hamper breast volume delineation. To overcome this limitation the breast contour is defined by palpation and then radio-opaque wire is put around it before the CT scan. To optimize assessment of breast margins in the cranial, caudal, medial, lateral and posterior directions, the present study evaluated palpation and CT and determined whether ultrasound (US) provided any added value. Methods Twenty consecutive patients were enrolled after they had provided informed consent to participating in this prospective study which was approved by the Regional Public Health Ethics Committee. Palpation and US defined breast margins and each contour was marked and outlined with a fine plastic wire. Breasts were then contoured on axial CT images using the breast window width (WW) and window level (WL) (401 and 750 Hounsfield Units –HU- respectively), at which setting the plastic wires were invisible. Then, the lung window function (WW 1601 HU; WL −300 HU) was inserted to visualize the plastic wires which were used as guidelines to contour the palpable and US breast volumes. As each wire had a different diameter, both volumes were easily defined on CT slices. Results were analyzed using descriptive statistics, percentage overlap and reproducibility measures (agreement and reliability). Results Volumes: US gave the largest and palpation the smallest. Agreement was best between palpation and CT. Reliability was almost perfect in all correlations. Extensions: Cranial and posterior were highest with US and smallest with palpation. Agreement was best between palpation and CT in all extensions except the cranial. Since strong to almost perfect agreement emerged for all comparisons, reliability was high. Conclusions US may be useful in defining the cranial and posterior extensions, mainly when tumours are localized there. This study demonstrates that the now standard radio-opaque wires around the palpable breast may not be needed in breast contouring.
- Full Text
- View/download PDF
20. EP-1182: FDG-PET does not predict outcome for early stage nonsmall- cell lung cancer after sterotactic body radiotherapy
- Author
-
Giampaolo Montesi, Vittorio Bini, E. Arena, Cynthia Aristei, Fabio Arcidiacono, Lorenzo Falcinelli, Simonetta Saldi, M. Porcari, Rita Bellavita, N. Baffa, and F. Paglione
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Hematology ,Radiation therapy ,Radiology Nuclear Medicine and imaging ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Non small cell ,Stage (cooking) ,business - Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.